NVP-ADW742

NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells[1][2].

Product Specifications

CAS Number

[475488-23-4]

Product Name Alternative

ADW742; GSK 552602A; ADW

UNSPSC

12352005

Hazard Statement

H317, H319

Target

Apoptosis; IGF-1R; Insulin Receptor

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/NVP-ADW742.html

Purity

99.30

Solubility

DMSO : 19.23 mg/mL (ultrasonic)

Smiles

NC1=C2C(N(C=C2C3=CC=CC(OCC4=CC=CC=C4)=C3)[C@H]5C[C@@H](C5)CN6CCCC6)=NC=N1

Molecular Formula

C28H31N5O

Molecular Weight

453.58

Precautions

H317, H319

References & Citations

[1]Mitsiades CS, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar;5 (3) :221-30.|[2]Warshamana-Greene GS, et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther. 2004 May;3 (5) :527-35.